In the quiet of a biology lab at UC San Diego, researchers have enlisted machine learning to do what centuries of traditional experimentation could not: locate the rarest functional DNA sequences hidden within a space of millions of possibilities. Building on prior work mapping the genetic gateways that govern roughly a third of human genes, the team trained AI models to design sequences with species-specific gene activation properties — a feat that compresses what would have been geological timescales of laboratory work into hours. It is a reminder that intelligence, whether biological or art
News-Medical.net
· May 19, 2023
· technology
· 3 min de leitura
High
Apuração: Verificado
UC San Diego researchers use AI to design custom DNA sequences for gene activation
◉
Technology
6907 artigos relacionados
AI Industry Splits on Open Models as Anthropic, Tech Giants Push Back …
Google News · 100% correspondência
Samsung Galaxy Glasses Launch with Gemini AI, 9-Hour Battery This Fall
Business Today · 99% correspondência
Chip stocks plunge as AI investment doubts trigger global selloff
BBC News · 99% correspondência
Microsoft Launches A.I. Cybersecurity Tools Amid Rising Hacking Concer…
The New York Times · 99% correspondência
Microsoft Races to Weaponize AI Against AI Threats
The Star · 99% correspondência
Cobertura Relacionada
Reuters · Jul 29
Semiconductor Selloff Intensifies as Chip Stocks Enter Panic Territory
Semiconductor stocks are experiencing severe losses as market panic intensifies. The chip sector rout signals broader co…
IT Brief Australia · Jul 29 Sydney search engine NeoSearch opens code to challenge Google's dominanceSydney-based NeoSearch released its search engine code under Apache 2.0 license, allowing public inspection of its ranki…
Mongabay · Jul 29 Vietnam's rangers use AI and cameras to reverse wildlife poaching crisisVietnam's Pu Mat National Park antipoaching unit combines SMART software and remote cameras with ground patrols to comba…
Devdiscourse · Jul 29 African Digital Governance Gap: Policies Exist, But Control and Outcomes LagAfrican governments are rapidly digitizing public services but lack institutional capacity to govern these systems effec…
Viés e Enquadramento
⚖
Science reporting with neutral tone and minimal bias; presents research findings straightforwardly with appropriate context and future applications.
Bias Direction
center
Confidence
HIGH
Objective scientific reporting with contextual framing that connects AI to broader public awareness before narrowing to specific research application.
Ethical considerations or concerns about synthetic DNA design
Potential risks or limitations of the technology
Competing research or alternative approaches
Industry or commercial implications/concerns
Regulatory framework discussion
Impacto Geopolítico
🌎
UC San Diego AI-driven gene activation research advances synthetic biology capabilities with potential dual-use applications in biotechnology and medicine.
Escalation Risk
low
Confidence
MED
United States
Global biotechnology sector
International research community
Strengthens U.S. scientific leadership in AI-driven synthetic biology; potential competitive advantage in biotech innovation. May accelerate biotechnology development globally, with implications for which nations lead in gene therapy and synthetic biology markets.
Similar to the early recombinant DNA research era (1970s), where foundational scientific breakthroughs preceded regulatory frameworks and international governance discussions about dual-use research.
Lente Econômica
📈
UC San Diego researchers use AI to design custom DNA sequences for precise gene activation, enabling targeted biotechnology applications with potential therapeutic benefits.
Market Signal
bullish
Confidence
MED
Biotechnology
Pharmaceutical/Drug Development
Medical Devices
Genetic Engineering
Artificial Intelligence/Machine Learning
Healthcare/Gene Therapy
Consumers may eventually benefit from more precise, personalized gene therapies and targeted drug treatments with fewer side effects, though commercialization timelines remain uncertain. Healthcare costs could decrease long-term if treatments become more efficient.
Regulatory bodies (FDA, EMA) may need to establish new frameworks for evaluating AI-designed synthetic DNA sequences and gene therapies. Intellectual property policies around AI-generated genetic designs require clarification. Bioethics oversight of custom gene activation applications will likely intensify.